Literature DB >> 26028517

Docetaxel for advanced prostate cancer: how early to start?

Andrew J Armstrong1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26028517     DOI： 10.1016/S1470-2045(15)00012-1

Source DB:  PubMed          Journal:  Lancet Oncol        ISSN： 1470-2045            Impact factor:   41.316


× No keyword cloud information.
  2 in total

1.  Proscillaridin A slows the prostate cancer progression through triggering the activation of endoplasmic reticulum stress.

Authors:  Fan Wang; Lin Liu; Yu Tong; Linfeng Li; Yanfeng Liu; Wei-Qiang Gao
Journal:  Cell Cycle       Date:  2020-02-02       Impact factor: 4.534

2.  Prognostic value of a computer-aided diagnosis system involving bone scans among men treated with docetaxel for metastatic castration-resistant prostate cancer.

Authors:  Koichi Uemura; Yasuhide Miyoshi; Takashi Kawahara; Shuko Yoneyama; Yusuke Hattori; Jun-ichi Teranishi; Keiichi Kondo; Masatoshi Moriyama; Shigeo Takebayashi; Yumiko Yokomizo; Masahiro Yao; Hiroji Uemura; Kazumi Noguchi
Journal:  BMC Cancer       Date:  2016-02-16       Impact factor: 4.430
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.